Alkem Laboratories · NSE: ALKEM · BSE: 539523
Q2 FY25 results · Jul–Sep 2024
Alkem Laboratories reported revenue from operations of ₹3,414.67 crore (down 0.7% from Q2 FY24) and net profit of ₹701.96 crore (up 14.2% from Q2 FY24) for Q2 FY25 (Jul–Sep 2024), on a consolidated basis.
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,414.67 | 3,440.17 | −0.7% | 3,031.82 | +12.6% |
| Other income | 134.48 | 63.19 | +112.8% | 120.31 | +11.8% |
| Total income | 3,549.15 | 3,503.36 | +1.3% | 3,152.13 | +12.6% |
| Profit before tax | 780.26 | 648.04 | +20.4% | 619.36 | +26.0% |
| Net profit for the period | 701.96 | 614.89 | +14.2% | 550.24 | +27.6% |
| Attributable to shareholders of the company | 688.64 | 620.52 | +11.0% | 545.16 | +26.3% |
| EPS, basic (₹) | 57.60 | 51.90 | +11.0% | 45.60 | +26.3% |
| Net margin (%) | 20.6 | 17.9 | 18.1 |
| Item | Q2 FY25 | Q2 FY24 | YoY | Q1 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,871.97 | 2,634.59 | +9.0% | 2,500.10 | +14.9% |
| Other income | 120.19 | 61.84 | +94.4% | 106.10 | +13.3% |
| Total income | 2,992.16 | 2,696.43 | +11.0% | 2,606.20 | +14.8% |
| Profit before tax | 767.67 | 638.72 | +20.2% | 640.94 | +19.8% |
| Net profit for the period | 697.58 | 646.51 | +7.9% | 583.25 | +19.6% |
| EPS, basic (₹) | 58.34 | 54.07 | +7.9% | 48.78 | +19.6% |
| Net margin (%) | 24.3 | 24.5 | 23.3 |
Consolidated
- Filed with BSE
- 13 Nov 2024, 16:31 IST
- Board meeting
- 13 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2024, 16:31 IST
- Board meeting
- 13 Nov 2024
- Period
- 01 Jul 2024 to 30 Sep 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE